The Covid-19 vaccine from Pfizer Inc. and BioNTech SE is still highly effective at protecting against symptomatic Covid-19 for at least six months after the second dose, the companies said.
The findings, released Thursday, emerged from a continuing review of how volunteers in the shot’s late-stage trial were faring.
The further analysis suggested the vaccine worked effectively against a variant first identified in South Africa, Pfizer and BioNTech said. And the companies said they haven’t found serious safety concerns so far.
“It is an important step to further confirm the strong efficacy and good safety data we have seen so far, especially in a longer-term follow-up,” said BioNTech Chief Executive Ugur Sahin.
Pfizer Chief Executive Albert Bourla said the additional results provide “further confidence in our vaccine’s overall effectiveness.”
